X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2026-11-06 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $316.00 | -3,150 | 448,373 | -1% | -$995,405 | ||||||
2026-11-06 | XGN | Exagen Inc. | Chernett Jorey | 10% | S - Sale | $6.14 | -11,265 | 2,625,625 | 0% | -$69,167 | ||||||
| M | 2026-11-09 | XGN | Exagen Inc. | Chernett Jorey | 10% | P - Purchase | $5.85 | +15,585 | 2,625,625 | +1% | +$91,242 | |||||
| D | 2026-11-05 | CDNA | Caredx, Inc. | Kennedy Keith | CFO, COO | S - Sale+OE | $77.82 | -61,961 | 199,147 | -24% | -$4,821,711 | |||||
| D | 2026-11-03 | DGX | Quest Diagnostics Inc | Doherty Catherine T. | EVP | S - Sale+OE | $248.02 | -22,105 | 76,501 | -22% | -$5,482,442 | |||||
2026-11-03 | LH | Labcorp Holdings Inc. | Vaughn Bryan T | EVP, Pres, Diagnostics | S - Sale | $353.70 | -306 | 6,845 | -4% | -$108,232 | ||||||
2026-11-02 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $399.97 | -112 | 234,074 | 0% | -$44,797 | ||||||
2026-11-02 | NTRA | Natera, Inc. | Rabinowitz Matthew | Exec COB | S - Sale | $400.02 | -748 | 2,116,928 | 0% | -$299,214 | ||||||
2026-11-02 | NTRA | Natera, Inc. | Rabinowitz Daniel | SEC., GC | S - Sale | $400.05 | -341 | 167,880 | 0% | -$136,416 | ||||||
2026-11-02 | NTRA | Natera, Inc. | Moshkevich Solomon | Pres, CLINICALDIAGNOSTICS | S - Sale | $409.77 | -3,419 | 101,323 | -3% | -$1,400,994 | ||||||
2026-11-02 | NTRA | Natera, Inc. | Fesko John | Pres, CHIEF BUS. OFFICER | S - Sale | $400.01 | -302 | 195,276 | 0% | -$120,804 | ||||||
2026-11-02 | NTRA | Natera, Inc. | Chapman Steven Leonard | CEO, Pres | S - Sale | $411.80 | -3,801 | 87,431 | -4% | -$1,565,239 | ||||||
| M | 2026-11-02 | NTRA | Natera, Inc. | Brophy Michael Burkes | CFO | S - Sale | $394.97 | -795 | 45,779 | -2% | -$313,998 | |||||
2026-11-02 | BLLN | Billiontoone, Inc. | Ten Bosch John Roderick | SVP of Laboratory Operations | S - Sale | $113.17 | -2,834 | 16,551 | -15% | -$320,724 | ||||||
| D | 2026-11-02 | BLLN | Billiontoone, Inc. | Atay Oguzhan | COB, CEO | S - Sale+OE | $109.93 | -30,335 | 141,167 | -18% | -$3,334,642 | |||||
| D | 2026-11-02 | BLLN | Billiontoone, Inc. | Tsao David | CTO | S - Sale+OE | $109.24 | -20,000 | 1,000 | -95% | -$2,184,854 | |||||
2026-11-03 | PSNL | Personalis, Inc. | Hall Christopher M | CEO | S - Sale | $15.87 | -29,112 | 199,415 | -13% | -$462,007 | ||||||
2026-11-02 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale | $36.10 | -14,496 | 155,942 | -9% | -$523,330 | ||||||
2026-10-30 | LH | Labcorp Holdings Inc. | Parham Richelle P | Dir | S - Sale | $361.22 | -1,078 | 2,288 | -32% | -$389,395 | ||||||
| M | 2026-10-28 | NTRA | Natera, Inc. | Brophy Michael Burkes | CFO | S - Sale | $425.90 | -3,084 | 46,574 | -6% | -$1,313,470 | |||||
| D | 2026-10-28 | BLLN | Billiontoone, Inc. | Atay Oguzhan | COB, CEO | S - Sale+OE | $118.00 | -11,000 | 146,501 | -7% | -$1,298,000 | |||||
2026-10-28 | CSTL | Castle Biosciences Inc | Juvenal Tobin W | Chief Commercial Officer | S - Sale | $36.42 | -6,578 | 38,853 | -14% | -$239,591 | ||||||
| M | 2026-10-27 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $413.96 | -478 | 234,186 | 0% | -$197,872 | |||||
2026-10-27 | NTRA | Natera, Inc. | Rabinowitz Matthew | Exec COB | S - Sale | $406.00 | -1,718 | 2,117,676 | 0% | -$697,508 | ||||||
| M | 2026-10-27 | NTRA | Natera, Inc. | Rabinowitz Daniel | SEC., GC | S - Sale | $416.63 | -1,852 | 168,221 | -1% | -$771,602 | |||||
| M | 2026-10-27 | NTRA | Natera, Inc. | Moshkevich Solomon | Pres, CLINICALDIAGNOSTICS | S - Sale | $416.88 | -2,172 | 104,742 | -2% | -$905,468 | |||||
| M | 2026-10-27 | NTRA | Natera, Inc. | Fesko John | Pres, CHIEF BUS. OFFICER | S - Sale | $416.88 | -1,679 | 195,578 | -1% | -$699,940 | |||||
| M | 2026-10-27 | NTRA | Natera, Inc. | Chapman Steven Leonard | CEO, Pres | S - Sale | $418.25 | -5,694 | 91,232 | -6% | -$2,381,532 | |||||
| M | 2026-10-27 | NTRA | Natera, Inc. | Brophy Michael Burkes | CFO | S - Sale | $418.31 | -1,979 | 49,658 | -4% | -$827,842 | |||||
2026-10-26 | DGX | Quest Diagnostics Inc | Pfeiffer Gary M | Dir | S - Sale | $243.00 | -1,203 | 29,802 | -4% | -$292,329 | ||||||
2026-10-26 | CSTL | Castle Biosciences Inc | Juvenal Tobin W | Chief Commercial Officer | S - Sale | $33.08 | -3,288 | 45,431 | -7% | -$108,767 | ||||||
| DM | 2026-09-24 | VCYT | Veracyte, Inc. | Holstein Jens | Dir | S - Sale+OE | $48.50 | -15,000 | 27,471 | -35% | -$727,500 | |||||
| D | 2026-10-27 | VCYT | Veracyte, Inc. | Eastham Karin | Dir | S - Sale+OE | $50.00 | -14,850 | 10,247 | -59% | -$742,573 | |||||
2026-10-21 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $410.55 | -3,150 | 234,664 | -1% | -$1,293,246 | ||||||
2026-10-19 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale | $31.91 | -14,496 | 170,438 | -8% | -$462,567 | ||||||
2026-10-16 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $402.47 | -1,500 | 237,814 | -1% | -$603,710 | ||||||
2026-10-19 | VCYT | Veracyte, Inc. | Bhanji Muna | Dir | S - Sale | $43.70 | -1,864 | 40,854 | -4% | -$81,457 | ||||||
2026-10-19 | XGN | Exagen Inc. | Chernett Jorey | 10% | P - Purchase | $7.46 | +14,000 | 2,618,540 | +1% | +$104,440 | ||||||
| D | 2026-10-16 | GH | Guardant Health, Inc. | Tariq Musa | Dir | S - Sale+OE | $165.88 | -116 | 11,583 | -1% | -$19,242 | |||||
2026-10-16 | XGN | Exagen Inc. | Aballi John | Pres, CEO | S - Sale | $7.87 | -34,294 | 845,941 | -4% | -$269,791 | ||||||
| D | 2026-10-15 | NTRA | Natera, Inc. | Rabinowitz Matthew | Exec COB | S - Sale+OE | $402.64 | -50,000 | 4,282,188 | -1% | -$20,132,028 | |||||
| DM | 2026-10-14 | BLLN | Billiontoone, Inc. | Atay Oguzhan | COB, CEO | S - Sale+OE | $99.14 | -11,000 | 149,168 | -7% | -$1,090,575 | |||||
2026-10-15 | GRAL | Grail, Inc. | Ofman Joshua J. | CEO | S - Sale | $136.85 | -20,000 | 342,271 | -6% | -$2,736,945 | ||||||
2026-10-14 | GH | Guardant Health, Inc. | Azar Alex M II | Dir | S - Sale | $159.89 | -69 | 893 | -7% | -$11,032 | ||||||
| D | 2026-10-12 | BLLN | Billiontoone, Inc. | Atay Oguzhan | COB, CEO | S - Sale+OE | $94.31 | -19,334 | 151,835 | -11% | -$1,823,450 | |||||
2026-10-12 | CSTL | Castle Biosciences Inc | Juvenal Tobin W | Chief Commercial Officer | S - Sale | $33.64 | -3,288 | 48,719 | -6% | -$110,608 | ||||||
2026-10-12 | SERA | Sera Prognostics, Inc. | Inglis Tiffany Eul Davis | Chief Medical Officer | S - Sale | $2.03 | -8,024 | 83,565 | -9% | -$16,289 | ||||||
2026-10-05 | BLLN | Billiontoone, Inc. | Ten Bosch John Roderick | SVP of Laboratory Operations | S - Sale | $105.15 | -2,834 | 19,385 | -13% | -$297,995 | ||||||
| D | 2026-10-05 | BLLN | Billiontoone, Inc. | Tsao David | CTO | S - Sale+OE | $108.15 | -20,000 | 1,000 | -95% | -$2,162,950 | |||||
2026-10-05 | GRAL | Grail, Inc. | Partridge Andrew John | Chief Growth Officer | S - Sale | $146.39 | -7,873 | 155,865 | -5% | -$1,152,528 | ||||||
2026-10-05 | GRAL | Grail, Inc. | Freidin Aaron | CFO | S - Sale | $146.39 | -23,619 | 225,364 | -9% | -$3,457,585 | ||||||
| D | 2026-10-05 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale+OE | $35.57 | -14,496 | 184,934 | -7% | -$515,565 | |||||
| D | 2026-10-01 | CSTL | Castle Biosciences Inc | Oelschlager Kristen M | COO | S - Sale+OE | $35.95 | -4,153 | 86,005 | -5% | -$149,318 | |||||
2026-10-01 | NTRA | Natera, Inc. | Chapman Steven Leonard | CEO, Pres | S - Sale | $413.31 | -1,273 | 96,926 | -1% | -$526,144 | ||||||
2026-10-01 | NTRA | Natera, Inc. | Moshkevich Solomon | Pres, CLINICALDIAGNOSTICS | S - Sale | $414.22 | -3,000 | 106,914 | -3% | -$1,242,645 | ||||||
| M | 2026-09-29 | CSTL | Castle Biosciences Inc | Juvenal Tobin W | Chief Commercial Officer | S - Sale | $35.29 | -6,577 | 52,007 | -11% | -$232,128 | |||||
| D | 2026-09-28 | BLLN | Billiontoone, Inc. | Atay Oguzhan | COB, CEO | S - Sale+OE | $120.64 | -10,999 | 154,502 | -7% | -$1,326,919 | |||||
| D | 2026-09-24 | BLLN | Billiontoone, Inc. | Tsao David | CTO | S - Sale+OE | $125.00 | -3,333 | 1,000 | -77% | -$416,625 | |||||
2026-09-24 | BLLN | Billiontoone, Inc. | Ten Bosch John Roderick | SVP of Laboratory Operations | S - Sale | $120.00 | -1,416 | 22,219 | -6% | -$169,920 | ||||||
2026-09-23 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $388.01 | -18,064 | 239,314 | -7% | -$7,008,972 | ||||||
2026-09-21 | BLLN | Billiontoone, Inc. | Ten Bosch John Roderick | SVP of Laboratory Operations | S - Sale | $106.61 | -1,416 | 23,635 | -6% | -$150,960 | ||||||
2026-09-22 | CAI | Caris Life Sciences, Inc. | Denton John Russel | See Remarks | S - Sale | $31.82 | -7,500 | 184,039 | -4% | -$238,626 | ||||||
2026-09-21 | GRAL | Grail, Inc. | Freidin Aaron | CFO | S - Sale | $93.34 | -4,100 | 248,983 | -2% | -$382,679 | ||||||
| D | 2026-09-21 | GRAL | Grail, Inc. | Ofman Joshua J. | CEO | S - Sale+OE | $97.74 | -61,452 | 362,271 | -15% | -$6,006,378 | |||||
| D | 2026-09-21 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale+OE | $35.33 | -14,496 | 191,265 | -7% | -$512,202 | |||||
2026-09-21 | VCYT | Veracyte, Inc. | Leite John | Global Chief Commercial Off | S - Sale | $40.00 | -4,015 | 124,329 | -3% | -$160,600 | ||||||
2026-09-18 | PSNL | Personalis, Inc. | Moore Stephen Michael | SVP, GC | S - Sale | $16.22 | -2,068 | 90,257 | -2% | -$33,543 | ||||||
2026-09-18 | PSNL | Personalis, Inc. | Chen Richard | Pres, CMO | S - Sale | $16.22 | -3,998 | 169,882 | -2% | -$64,848 | ||||||
2026-09-18 | PSNL | Personalis, Inc. | Hall Christopher M | CEO | S - Sale | $16.22 | -7,459 | 228,527 | -3% | -$120,985 | ||||||
2026-09-18 | PSNL | Personalis, Inc. | Tachibana Aaron | CFO, COO | S - Sale | $16.22 | -2,931 | 195,902 | -1% | -$47,541 | ||||||
| D | 2026-09-17 | BLLN | Billiontoone, Inc. | Lynch Thomas P. | See Remarks | S - Sale+OE | $110.33 | -35,112 | 700 | -98% | -$3,873,966 | |||||
| M | 2026-09-15 | NTRA | Natera, Inc. | Sheena Jonathan | CO-FOUNDER | S - Sale | $351.49 | -9,150 | 257,378 | -3% | -$3,216,145 | |||||
| D | 2026-09-17 | CAI | Caris Life Sciences, Inc. | Brille Brian J | See Remarks | S - Sale+OE | $30.33 | -400,000 | 730,303 | -35% | -$12,132,080 | |||||
2026-09-15 | GH | Guardant Health, Inc. | Chudova Darya | CTO | S - Sale | $178.00 | -7,738 | 70,635 | -10% | -$1,377,364 | ||||||
2026-09-16 | GH | Guardant Health, Inc. | Krognes Steve E. | Dir | S - Sale | $175.74 | -6,674 | 7,906 | -46% | -$1,172,886 | ||||||
2026-09-16 | GH | Guardant Health, Inc. | Azar Alex M II | Dir | S - Sale | $175.00 | -826 | 825 | -50% | -$144,550 | ||||||
| D | 2026-09-16 | GH | Guardant Health, Inc. | Tariq Musa | Dir | S - Sale+OE | $175.00 | -116 | 11,449 | -1% | -$20,300 | |||||
| M | 2026-09-14 | NTRA | Natera, Inc. | Rabinowitz Matthew | Exec COB | S - Sale | $341.15 | -102,000 | 2,125,394 | -5% | -$34,797,271 | |||||
| D | 2026-09-14 | BLLN | Billiontoone, Inc. | Atay Oguzhan | COB, CEO | S - Sale+OE | $99.91 | -30,331 | 157,168 | -16% | -$3,030,444 | |||||
| M | 2026-09-14 | CSTL | Castle Biosciences Inc | Juvenal Tobin W | Chief Commercial Officer | S - Sale | $33.73 | -6,600 | 58,584 | -10% | -$222,621 | |||||
2026-09-14 | VCYT | Veracyte, Inc. | Holstein Jens | Dir | S - Sale | $40.95 | -5,000 | 27,471 | -15% | -$204,747 | ||||||
2026-09-14 | YDES | Yd Bio Ltd | Shen Ethan Phd | CEO | P - Purchase | $3.85 | +12,700 | 54,379,189 | 0% | +$48,895 | ||||||
| D | 2026-09-11 | CSTL | Castle Biosciences Inc | Maetzold Derek J | Pres, Chief Exec. Officer | S - Sale+OE | $32.02 | -14,518 | 197,181 | -7% | -$464,870 | |||||
2026-09-11 | GH | Guardant Health, Inc. | Kalia Kumud | CIO | S - Sale | $158.05 | -4,000 | 39,794 | -9% | -$632,193 | ||||||
2026-09-11 | NTRA | Natera, Inc. | Rabinowitz Matthew | Exec COB | S - Sale | $327.97 | -50,000 | 2,227,394 | -2% | -$16,398,267 | ||||||
2026-09-09 | BLLN | Billiontoone, Inc. | Ten Bosch John Roderick | SVP of Laboratory Operations | S - Sale | $97.54 | -1,416 | 25,051 | -5% | -$138,117 | ||||||
| D | 2026-09-09 | BLLN | Billiontoone, Inc. | Tsao David | CTO | S - Sale+OE | $98.77 | -20,000 | 1,000 | -95% | -$1,975,400 | |||||
2026-09-10 | SERA | Sera Prognostics, Inc. | Anderson Dyaarl Lee Jr. | Chief Commercial Officer | S - Sale | $2.00 | -1,800 | 76,198 | -2% | -$3,600 | ||||||
2026-09-10 | SERA | Sera Prognostics, Inc. | Lindgardt Zhenya | CEO | S - Sale | $2.00 | -7,022 | 837,848 | -1% | -$14,044 | ||||||
2026-09-10 | SERA | Sera Prognostics, Inc. | Inglis Tiffany Eul Davis | Chief Medical Officer | S - Sale | $2.00 | -486 | 91,589 | -1% | -$972 | ||||||
2026-09-10 | SERA | Sera Prognostics, Inc. | Jackson Benjamin | GC | S - Sale | $2.00 | -2,190 | 159,566 | -1% | -$4,380 | ||||||
| D | 2026-09-09 | FTRE | Fortrea Holdings Inc. | Russell Carrie Elizabeth | Interim CAO | S - Sale+OE | $16.85 | -246 | 2,384 | -9% | -$4,145 | |||||
| D | 2026-09-09 | FTRE | Fortrea Holdings Inc. | Morais Mark A. | COO | S - Sale+OE | $16.85 | -3,149 | 86,419 | -4% | -$53,061 | |||||
2026-09-09 | YDES | Yd Bio Ltd | Shen Ethan Phd | CEO | P - Purchase | $3.93 | +3,100 | 54,366,489 | 0% | +$12,183 | ||||||
2026-09-08 | SERA | Sera Prognostics, Inc. | Lindgardt Zhenya | CEO | S - Sale | $2.00 | -20,139 | 844,870 | -2% | -$40,278 | ||||||
2026-09-04 | YDES | Yd Bio Ltd | Shen Ethan Phd | CEO | P - Purchase | $3.67 | +18,378 | 54,363,389 | 0% | +$67,447 | ||||||
2026-09-04 | VCYT | Veracyte, Inc. | Febbo Phillip G. | Chief Scientific, Med Officer | S - Sale | $43.05 | -13,110 | 133,048 | -9% | -$564,410 | ||||||
2026-09-04 | VCYT | Veracyte, Inc. | Chambers Rebecca | CFO | S - Sale | $43.10 | -3,652 | 166,025 | -2% | -$157,394 | ||||||
2026-09-04 | VCYT | Veracyte, Inc. | McGuire Annie | EVP, GC | S - Sale | $43.09 | -3,254 | 131,160 | -2% | -$140,212 | ||||||
| DM | 2026-09-03 | CAI | Caris Life Sciences, Inc. | Spetzler David Baxley | Pres | S - Sale+OE | $24.84 | -597,212 | 1,182,871 | -34% | -$14,834,107 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |